-logo-1200x675.png?v=20240604092546){kind=logo}
Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2027 earnings estimates for Swedish Orphan Biovitrum in a research note issued on Friday, September 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $0.67 per share for the quarter, down from their previous estimate of $0.68. The consensus estimate for Swedish Orphan Biovitrum’s current full-year earnings is $1.91 per share.
BIOVF has been the subject of a number of other reports. Pareto Securities lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Monday, June 29th. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.
Swedish Orphan Biovitrum Stock Performance
OTCMKTS BIOVF opened at $48.13 on Thursday. Swedish Orphan Biovitrum has a 1 year low of $29.18 and a 1 year high of $49.03. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. The stock has a market capitalization of $17.13 billion, a PE ratio of 106.95 and a beta of 0.33. The company’s 50 day simple moving average is $48.39 and its two-hundred day simple moving average is $45.71.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.
Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.
See Also
- Five stocks we like better than Swedish Orphan Biovitrum
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
